n recent years, China’s healthcare reform has been largely focused on speed, particularly through the acceleration of regulatory review processes and the expansion of patient access to innovative medicines. Regulatory timelines have shortened through the introduction of flexible pathways such as priority review, breakthrough designation, and conditional approval, while clinical development has been further accelerated by the implementation of a 30-day review timeline for IND applications. As a result, China’s historical drug lag has narrowed, with an increasing number of products now submitted simultaneously or even first in China within the global landscape.

In 2025, the National Medical Products Administration (NMPA) approved a record number of new medicines. In parallel, the updating mechanism of the National Reimbursement Drug List (NRDL) has shifted from a multiyear cycle to an annual process, shortening the time between regulatory approval and reimbursement listing under the national health insurance system. This emphasis on speed has become a defining and widely recognized part of China’s healthcare reform.

However, another message emerged clearly from the China Town Hall at DIA Europe 2026: China’s next phase may be shaped not only by how quickly medicines reach the market, but by how they demonstrate value after launch through the National Healthcare Security Administration’s (NHSA’s) latest initiative: A Real-World Value Evaluation system to support health insurance decision-making, described as the “R-VALUE” framework, aimed at promoting the systematic generation of Real-World Evidence (RWE) to inform post-market evaluation of innovative health technologies.

A Still-Evolving Reform Story

China’s regulatory reforms have focused on faster approval and on encouraging simultaneous global development and submission of medicines; this agenda remains strong and evolving. But the R-VALUE framework announced in January 2026 (Draft guidance issued in Chinese only) made clear that the policy conversation is now moving further to payer decision-making. The question for China is no longer only how to bring new products to market more quickly, but also how to use health insurance resources in a way that is fair, sustainable, and more closely aligned with real patient benefit in China. In a nutshell, the NHSA R-VALUE framework aims to use trusted RWE to assess the clinical and broader value of medicines across their lifecycle to support reimbursement and other healthcare decisions. The public consultation on the framework concluded on 30 January 2026, and the pilot initiative is already operational. Under the implementation plan, 2026 is designated as the practice stage, followed by further phased development and application in 2027.

This shift is important because it changes the role of evidence in reimbursement decision-making. The payer is no longer asking only whether a medicine works under ideal or controlled trial conditions. Instead, it is asking how the medicine performs in real clinical practice, how much incremental benefit it provides compared with existing options, which patient populations benefit most, and whether that level of value is sufficient to justify public reimbursement. The NHSA’s R-VALUE framework is explicit on this point: The draft guidance published in January 2026 prioritizes evaluating medicines approved by NMPA on the basis of pivotal trials using single-arm designs or surrogate endpoints, especially conditionally approved medicines, and encourages the use of clinical endpoints such as overall survival.

More Than Just Another RWE Initiative

The use of RWE in regulatory and health technology assessment (HTA) decision-making is not new. Previous research has shown that regulatory and HTA agencies have increasingly incorporated RWE into their evaluations, with many authorities issuing official guidance on the generation and use of RWE. Since 2020, the Center for Drug Evaluation (CDE) of the NMPA has released a series of technical guidelines covering the generation, quality requirements, study design, and regulatory application of RWE across the product lifecycle. These guidelines clarify when and how RWE may be used to support drug approval, indication expansion, label modification, and post-marketing safety evaluation, with particular emphasis on data governance, bias control, and methodological rigor.

Building on this, the new direction in China is more than just another call for more real-world evidence; it’s a systematic framework from concept through methodology and to structural setup in order to use the RWE to directly support payer decision-making. The NHSA R-VALUE draft guidance outlines a structured architecture for the R-VALUE framework built around four core elements:

1. Common technical standards for study design, data sources, and analytical methods;
2. A standardized seven-step process spanning proposal development, protocol design, implementation, reporting, and data archiving;
3. A national network of 79 designated trusted sites within China to ensure data quality and scientific credibility; and
4. A clear focus on assessing the real-world clinical and economic value of innovative technologies in routine clinical practice.

This framework is supported by policy incentives. For example, two potential mechanisms were proposed in the draft guidance that linked to RWE in the National Reimbursement Drug List (NRDL) process. First, a newly approved drug with a completed value assessment with relevant RWE results may receive flexible pricing incentives during NRDL negotiations. Second, for drugs with insufficient evidence or uncertainty around efficacy/safety, a tiered incentive mechanism can be provided during the NRDL process on the condition that companies commit to conducting post-listing RWE studies. However, these incentives are accompanied by accountability measures: if the promised studies are not completed, or if the resulting evidence does not confirm the expected value, payment terms may be adjusted and the medicine may be subject to renegotiation.

Seen from this perspective, China is not just asking for more data, it is moving toward a systematic approach to incorporating RWE into reimbursement decision-making.

A Direction That Resonates Internationally

From an international perspective, these underlying questions in China are also being considered by many other health systems:

• How to assess value when clinical trial evidence is limited or based on surrogate endpoints;
• How to manage the uncertainty in accelerated approvals; and
• How to use RWE in decision-making without compromising methodological standards.

Randomized controlled trials (RCTs) remain essential in regulatory and reimbursement decision-making, but RWE can help determine a treatment’s benefits in routine clinical care, how patient adherence influences real-world value, whether comparative effectiveness can be better understood in the absence of direct head-to-head trials, and longer-term safety, outcomes, and economic impact.

Several processes and mechanisms are in place internationally: The European Medicines Agency’s (EMA) DARWIN EU initiative represents a federated real-world data network across Europe to generate RWE studies that inform regulatory decision-making. In England, NICE’s Managed Access (MA) allows patients to access promising new treatments for a defined period while further data collection such as RWE is conducted to address clinical or cost-effectiveness uncertainties.

In this sense, China is part of a broader global discussion, but it is doing so with increasing scale and ambition: China is not only a major commercial market; it is increasingly a market whose payer decisions may shape how global companies think about the evidence they generate across the product lifecycle.

Looking Ahead

Methodological and structural guidances make this ambition clear. However, how this framework will play out in practice remains unknown. Key questions include:

• How predictable will the system be for companies that must decide whether to invest in RWE generation?
• Which outcomes will matter in decision-making, such as survival, functional status, and quality of life, or treatment persistence and adherence?
• How transparent will public reporting of methods and results be?
• How will incentives for the generation and use of RWE be operationalized within the national reimbursement process?

An additional open question is how far evidence generated in China will travel usefully across borders, and to what extent it may inform payer or HTA discussions in other jurisdictions.

The answers to these questions will be important factors in determining whether the new framework evolves into a durable decision-making tool.

The NHSA draft guidance addressed some of these potential challenges by emphasizing unified guidance, verifiable data, robust quality control, and early and broad participation from key stakeholders. However, the ultimate measure of success will be whether these principles translate into evidence that can be used for payer decision-making, and whether patients ultimately gain better access to innovations.

For the international pharmaceutical industry and researchers, this is a moment worth watching closely. China is not merely adding another RWE initiative; it is building an emerging, structured, payer-oriented value evaluation system, one that remains in active development and will require further implementation experience before its predictability and impact can be fully assessed. China’s earlier reforms demonstrated what could be achieved when the system is focused on speed to innovation. Its next phase is to assess how a major health system determines which innovations are truly worth paying for, and how integrated evidence generation plans from RCT to RWE will support regulatory and payer decision-making.